Viking Therapeutics, Inc. (NASDAQ:VKTX)’s main metabolic therapy candidate, VK2735, is being developed as an injectable and oral medication. Phase 3 development for the injectable version is scheduled ...
Investing.com -- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli ...
Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for some time ...
Welcome to the fleet, Viking Vesta. Viking officially named its newest ocean ship at a traditional ceremony held in Split, Croatia. Norwegian journalist and philanthropist Lene Tangevald-Jensen, the ...
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply ...
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Viking Therapeutics, Inc. (NASDAQ:VKTX) and CordenPharma have concluded a multi-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback